A brief introductory video explaining Micropore's unique membrane-based system
Our unique technology
Back to Latest News
For drugs exhibiting poor pharmacokinetics, limited bioavailability and a high degree of toxicity, there is growing interest in the field of nano-medicine and the biocompatibility performance of liposomes and lipid nanoparticles.
Because of the amphiphilic phospholipid bilayer’s resemblance to the mammalian cell membrane, liposomes and lipid nanoparticles (LNPs) are able to shield a drug from detection by the immune system, allowing additional time to get to the point of need without triggering an immune response. This capability makes liposomes and lipid nanoparticles particularly suitable for the delivery of DNA and mRNA payloads for vaccines.For manufacturers seeking drug approval for controlled release therapeutics using liposomes and LNPs, stability under shelf and in vivo conditions has been a problem to date. This is particularly true if the API is released in unintended ways and locations through changes in temperature, pH or shear stress, particle fission & fusion, lipid oxidation and hydrolysis, leakage; and loss of hydrophilic cargoes. Control of the interaction between phospholipids and water molecules, is key to making liposomes and LNP structures with the desired morphology, encapsulation efficiency, stability and size. The FDA’s “Guidance for Industry” concerning liposome drug products emphasises the importance of size and size distribution as “critical quality attributes and essential components for stability.
Currently there are five main methods of making liposomes at lab scale, allowing for size control from around 20nm up to several microns and composing of one or more bilayers, and a smaller number of larger-scale techniques. However, all of these techniques have the potential to degrade the efficacy of APIs due to the application of mechanical stresses (e.g. high shear, sonication, high pressure, etc.), use of unsuitable chemicals (e.g. volatile organic solvents, etc.), or by producing extremes of pH. Commercially available high temperature methods, in which the lipids are heated to around 80oC, exemplify the challenges towards more widespread approval and uptake of these drug delivery systems.
Recent work by Micropore Technologies has demonstrated that their aseptic membrane-based technology, already used for the formation near mono-dispersed PLGA microspheres, can equally be used as a refined micro-mixer for liposome and lipid nanoparticle production. By enabling the mixing of two miscible liquids together in a controlled manner achieving very narrow size distribution at, or below, room temperature, damage from high temperatures, pressure or shear can effectively be eliminated.
At Micropore we enjoy working in partnership with our clients to solve formulation challenges and deliver the highest performing, most sustainable, most cost-effective formulated delivery systems.Ask An Expert
Keep up to date with innovations at Micropore. Sign up today to stay informed with innovations at Micropore and automatically receive the Micropore newsletter and webinar invites.